Atlas Trials

A Phase I Study to Evaluate Safety, Tolerability, and Immunogenicity of a PIKA COVID-19 Vaccine in Healthy Individuals

Clinical trial NCT05305300 · COMPLETED

Trial details

NCT number
NCT05305300
Sponsor
Yisheng Biopharma (Singapore) Pte. Ltd.
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
COVID-19 Pandemic
Start date
2021-10-18
Primary completion
2022-05-15
Enrollment
135

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.